Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Otsuka Pharmaceutical Development & Commercialization: Clinical Trials & FDA Approval Profile

Otsuka Pharmaceutical Development & Commercialization (Global / Institutional) sponsors 58 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 16 active protocols (9 recruiting now), 33 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)15.5%
Median Closed Enrollment vs National (145 pts)272 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Otsuka Pharmaceutical Development & Commercialization
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)58
Active Pipeline (Recruiting Now)16 (9)
Completed vs Stopped Early33 / 9 (15.5%)
Median Closed Actual Enrollment272 participants
Physical Hospital Site Disclosure46.1% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Otsuka Pharmaceutical Development & Commercialization
Hospital Research SiteLocationShared Protocols
University of South FloridaTampa, FL5
ProScience Research GroupCulver City, CA5
Oregon Health and Science University Knight Cancer InstitutePortland, OR4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Otsuka Pharmaceutical Development & Commercialization
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06971731A Study of JNT-517 in Participants With Phenylketonuria (PKU)Phase IIIRECRUITING
NCT06628128A Long-Term Study of JNT-517 in Participants With PhenylketonuriaPhase IIIRECRUITING
NCT07209761A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary TuberculosisPhase IIIRECRUITING
NCT04782258A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal RecessivePhase IIIRECRUITING
NCT07759154A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional DysregulationPhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Otsuka Pharmaceutical Development & Commercialization Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI